Dr. Murtaza Tambuwala is a Pharmaceutical and  Molecular scientist, with an undergraduate degree in Pharmacy and has completed a Masters's in Pharmaceutical Technology from the School of Pharmacy, Trinity College Dublin. Dr Tambuwala completed his doctoral research focused on the development of Colon targeted drug-delivery system, at the School of Medicine and Medical Sciences, University College Dublin (2011) under the tutelage of Prof. Cormac Taylor and Dr. Ivan Coulter (CEO of Sublimity Therapeutics); funded by Enterprise Partnership Doctoral Research Award from Irish Research Council.

He has undertaken postdoctoral training at Trinity Translational Medicine Institute, Trinity College Dublin under the tutelage of Prof. Padraic Fallon funded by a post-doctoral research award obtained from the Irish Research Council by Dr Tambuwala.

Dr Tambuwala joined Ulster University as a Lecturer in 2013 to establish his independent research in the field of Advanced Drug-delivery to combat inflammation, cancer, and infection and has published 119 peer-reviewed manuscripts and has authored 12 book chapters of books related to drug delivery. The over-arching aims of his research lab are to understand the mechanisms that regulate transcriptional events in inflammation and the development of cancer, identity novel drug targets, and develop novel drug-delivery systems to target novel drug targets.  In particular, he is interested in the regulation of global gene expression in response to the hypoxic environment of inflamed adipose tissue/tumor, and the modification of transcriptional regulators which underlies the induction of inflammation, development, and progression of cancer and infections. His research is focused on developing new therapeutics for chronic inflammatory diseases such as IBD, intestinal fibrosis, Alzheimer's, cardiovascular diseases, and colon & breast cancer. 

To achieve the overall objectives of the development of new and better medicines he is working on:

1. Developing novel drug delivery systems to target inflamed tissue, microbial infections, and cancer tumors.

2. Investigate the biomolecular mechanism of natural compounds in inflammation and cancer.

3. Use 3D printing technologies to develop personalised oral drug delivery system.

4. Application of 3D bioprinting to develop novel models for IBD, cardiovascular inflammation, colon, and breast cancer to reduce the use of animals in research.

Dr Tambuwala initiated and directs the MSc in Pharmaceutical Sciences via Distant learning (Online) and on-campus at Ulster University and is an active contributor in the delivery and development of the MPharm program at the School of Pharmacy and Pharmaceutical Sciences.

Dr Tambuwala also serves as a reviewer for UK research councils and several esteemed journals in the field of inflammatory bowel diseases and drug delivery.